Archive for the ‘Cell Therapy’ Category

Stem Cell Therapy Project
Daniel, John, Magno, Thahn, Victor, Vivian show the world just exactly what stem cells really are.

By: John Peterman

See more here:
Stem Cell Therapy Project - Video

Stem Cell Therapy - BioLogic Anti-Aging Skin Cream
http://www.ReadTheReviewsFirst.com Truvisage Anti-Aging Skin Care International Is Better Than Botox!

By: Greg Smith

View original post here:
Stem Cell Therapy - BioLogic Anti-Aging Skin Cream - Video

Stem Cell Therapy Anti Aging Skin Cream Review and Exclusive Deal
http://www.ReadTheReviewsFirst.com Truvisage Anti-Aging Skin Care International Is Better Than Botox!

By: Greg Smith

Follow this link:
Stem Cell Therapy Anti Aging Skin Cream Review and Exclusive Deal - Video

Stem Cell Therapy to Treat Equine Tendon Injuries
A brief explanation of tendon injuries and how stem cell therapy can be used to treat them.

By: Animal Science

Read the original here:
Stem Cell Therapy to Treat Equine Tendon Injuries - Video

Cell Therapy Limited on Crowdcube - Repairing Broken Hearts
HeartcelTM is a novel stem cell therapy that can regenerate the heart following heart failure - a Cell Therapy Ltd Medicine.

By: Cell Therapy Ltd

The rest is here:
Cell Therapy Limited on Crowdcube - Repairing Broken Hearts - Video

Stem Cell Therapy at EmCell clinic: Dr. Khalil Fadel story

By:

See the rest here:
Stem Cell Therapy at EmCell clinic: Dr. Khalil Fadel story - Video

Chuck Bednar for redOrbit.com Your Universe Online

A new stem cell gene therapy developed by researchers at UCLA is set to begin clinical trials early next year after the technique reportedly cured 18 children who were born without working immune systems due to a condition known as ADA-deficient Severe Combined Immunodeficiency (SCID) or Bubble Baby disease.

The treatment was developed by Dr. Donald Kohn, a member of the UCLA Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, and his colleagues, and according to the university, it is able to identify and correct faulty genes by using the DNA of the youngsters born with this life-threatening condition.

Left untreated, ADA-deficient SCID is often fatal within the first year of a childs life, reports Peter M. Bracke for UCLA. However, after more than three decades of research, Dr. Kohns team managed to develop a gene therapy that can safely restore the immune systems of children with the disease by using their own cells and with no noticeable side effects.

All of the children with SCID that I have treated in these stem cell clinical trials would have died in a year or less without this gene therapy, instead they are all thriving with fully functioning immune systems, Dr. Kohn, who is also a professor of pediatrics and of microbiology, immunology and molecular genetics, said in a recent statement.

Children born with SCID have to be isolated in a controlled environment for their own safety, because without an immune system, they are extremely vulnerable to illnesses and infections that could be deadly. While there are other treatments for ADA-deficient SCID, Dr. Kohn noted that they are not always optimal or feasible for many children. The new technique, however, provides them with a cure, and the chance to live a full healthy life.

SCID is an inherited immunodeficiency that is typically diagnosed about six months after birth, the researchers said, and children with the condition are so vulnerable to infectious diseases that even the common cold could prove fatal to them. This particular form of the condition causes cells to not create ADA, an enzyme essential for the production of the white blood cells which are a vital component of a healthy, normally-functioning immune system.

Approximately 15 percent of all SCID patients are ADA-deficient, according to the university, and these youngsters are typically treated by being injected twice per week with the required enzyme. This is a process that must continue throughout a patients entire life, and even then it doesnt always work to bring their immune systems to optimal levels. Alternately, they could undergo bone marrow transplants from matched siblings, but those matches are rare and the transplanted cells themselves are often rejected by the childs body.

Dr. Kohn and his colleagues tested two therapy regimens on 18 ADA-deficient SCID over the course of two multi-year clinical trials starting in 2009. During the trials, the blood stem cells of the patients were removed from their bone marrow and genetically modified in order to correct the defect. All 18 of the patients were cured.

The technique used a virus delivery system first developed in Dr. Kohns laboratory in the 1990s a technique which inserts the corrected gene that produces the ADA into the blood forming stem cells in the bone marrow. The genetically corrected blood-forming stem cells will then produce the T-cells required to combat infections.

Read more here:
New Stem Cell Treatment Found To Cure 'Bubble Baby' Disease

AVON LAKE, OH (WOIO) - When Shannon Goulding's bloodhound Butler tore a ligament in his knee his entire personality changed.

"He was sedentary, and he wasn't as active as before," said Goulding.

Dr. Petti a veterinarianat the Avon Lake Animal Clinic told Goulding, who also works at the clinic, suggested that stem cell therapy could help.

"Watching him walk he looked stiff and uncomfortable," said Petti.

The therapy was successful. Goulding said after four weeks after the surgery she could see a change the way Butler moved.

Stem cell therapy helps animals suffering from sore knees and joints by using their own fat cells.

"You take them from the patient, you process them, make them active, and then you re inject them into the parts of the animal that are giving them problems," said Petti.

Petti said Avon Lake Animal Clinic has helped about 15 animals with stem cell therapy and people from all over the country have been calling.

One injection of stem cells can last up to three years, and after that a second injection may be needed.

Stem cell therapy is also an expensive procedure. It ranges from $2,000-2,500, but for Goulding she says seeing Butler run free without pain is worth it.

Follow this link:
Local clinic treats animals with stem cell therapy

Kilian Before After Stemlogix Stem Cell Therapy
dog with arthritis treated with autologous stem cells.

By: mark Greenberg

Excerpt from:
Kilian Before & After Stemlogix Stem Cell Therapy - Video

By: Adam Feuerstein | 11/18/14 - 10:16 AM EST

Inject a cocktail of undifferentiated stem cellsinto a patient who has suffered a heart attack, and days or even weekslater, the stem cells transform into cardiac cells and rebuild the damaged heart muscle. Months later, the patient has a "new" healthy heart.It's a great story. But so far, the proof remains elusive though not for a lack of trying.

The latest company to fulfill this ambitious scenario is NeoStem (NBS) which presented disappointing (but not surprising) results from a small study of its proprietary cardiac stem-cell therapy NBS10 at the American Heart Association annual meeting Monday. NeoStem tried to put some positive spin on the bad news but shares are down 25% to $5.10.

NBS10, formerly known as AMR-001, is an autologous stem-cell therapy derived from a patient's own bone marrow. When injected back into patients following a heart attack, the stem cells are supposed torestore blood flow, rebuild damaged cardiac muscle and improve function.

Except in NeoStem's study, NBS10 fell short on two primary endpoints designed to assess the therapy's efficacy. The study used non-invasive imaging to assess blood flow through the heart, six months after a single infusion of NBS10 or a placebo. There was no difference between NBS and placebo, NeoStem said.

The study's other co-primary efficacy endpoint was a measurement of adverse cardiac "MACE" events --defined as cardiovascular death, a repeatheart attack, heart failure hospitalization and coronary revascularization. To date, 17% of patientstreated with NBS10 have suffered a MACE event compared to 19% of patients in the placebo arm -- a difference which was not statistically significant.

NeoStem said NBS10 therapy was safe relative to placebo and that no patients treated with the stem cells have died compared to three deaths in the placebo patients. But with only one year of follow up on a small number of patients, any claims about a mortality benefit are clinically meaningless.

Read more:
NeoStem's Stem Cell Therapy Fails Mid-Stage Heart Attack Study

Contact Information

Available for logged-in reporters only

Newswise UCLA stem cell researchers have pioneered a stem cell gene therapy cure for children born with adenosine deaminase (ADA)-deficient severe combined immunodeficiency (SCID), often called Bubble Baby disease, a life-threatening condition that if left untreated can be fatal within the first year of life.

The groundbreaking treatment was developed by renowned stem cell researcher and UCLA Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research member Dr. Donald Kohn, whose breakthrough was developed over three decades of research to create a gene therapy that safely restores immune systems in children with ADA-deficient SCID using the patients own cells with no side effects.

To date, 18 children with SCID have been cured of the disease after receiving the stem cell gene therapy in clinical trials at UCLA and the National Institutes of Health.

All of the children with SCID that I have treated in these stem cell clinical trials would have died in a year or less without this gene therapy, instead they are all thriving with fully functioning immune systems said Kohn, a professor of pediatrics and of microbiology, immunology and molecular genetics in Life Sciences.

To protect children born with SCID they are kept in isolation, in controlled environments because without an immune system they are extremely vulnerable to illness and infection that could be lethal.

Other current options for treating ADA-deficient SCID are not always optimal or feasible for many children, said Kohn. We can now, for the first time, offer these children and their families a cure, and the chance to live a full healthy life.

Defeating ADA-Deficient SCID: A Game-Changing Approach

Children born with SCID, an inherited immunodeficiency, are generally diagnosed at about six months. They are extremely vulnerable to infectious diseases, and in a child with ADA-deficient SCID even the common cold can prove fatal. The disease causes cells to not create an enzyme called ADA, which is critical for production of the healthy white blood cells that drive a normal, fully-functioning immune system. About 15 percent of all SCID patients are ADA-deficient.

Read more here:
UCLA Stem Cell Researcher Pioneers Gene Therapy Cure for Children with "Bubble Baby" Disease

NEW YORK (TheStreet) -- Shares ofNeoStem (NBS) plummeted 25.52% to $5.05 in late morning trading Tuesdayafter the biotech company announced poor results from a trial of its proprietary cardiac stem-cell therapy NBS10.

NBS10, which used to be called AMR-001, missed two primary endpoints in the study to test the therapy's efficacy.The stem-cell therapy comesfrom a patient's own bone marrow and is injected into patients after a heart attack. The stem cells are then supposed to help blood flow and build cardiac muscle.

NeoStem's trial used non-invasive imaging to monitor blood flow through the heart six months after a one dose of NBS10 or a placebo. The study showed no difference between NBS and placebo, NeoStem said.

Must Read:NeoStem's Stem Cell Therapy Fails Mid-Stage Heart Attack Study

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Jim Cramer's protg, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

See the rest here:
NeoStem (NBS) Stock Plummets Today on Disappointing Cardiac Stem-Cell Therapy Data

CBS Los Angeles (con't)

Affordable Care Act Updates: CBSLA.com/ACA

Health News & Information: CBSLA.com/Health

WESTWOOD (CBSLA.com) Doctors say a groundbreaking stem cell therapy treatment out of UCLA may have cured Bubble Baby syndrome once and for all.

KNX 1070s Brian Ping reports Dr. Donald Kohn has perfected a gene therapy that has now cured 18 children born without an immune system, known as ADA-deficient severe combined immunodeficiency (SCID).

Only weeks after giving birth to fraternal twins in 2012, Alysia and Christian Padilla-Vaccaro found out their daughter Evangelinas immune system was so deficient that she could have no exposure to the outside world.

After enrolling their daughter in Dr. Donald Kohns revolutionary stem cell gene therapy treatment which was nearly three decades in the making doctors extracted stem cells from the bone marrow in Evangelinas hip, then used a modified mouse virus to correct her faulty gene before replacing the marrow.

You hear the words mouse virus and you want to run the other way, said mom Alysia. But they modify it so that its teaching it to do something that they want it to do, which is put something in there that was missing.

Evangelinas new immune system developed without side effects and she is now living a healthy normal life.

Her mother Alysia said while the process was difficult for any mom to go through, it was all worth it.

Read the original post:
UCLA Doctors Hail Potential Cure For Bubble Baby Syndrome

Clinical Trials: Advanced Cell Technology - Stem Cell Therapy
Last month (October 2014) in The Lancet, Advanced Cell Technology (ACT) published their preliminary phase 1 clinical data for their Stem Cell therapy trials for Stargardt #39;s Macular Dystrophy...

By: Essceejulies

Original post:
Clinical Trials: Advanced Cell Technology - Stem Cell Therapy - Video

Magnifisio dashed home strongly over 1400m to win Saturdays Lee-Steere Stakes at Ascot. Picture: Westernracepix

Sprinter Smoko will have stem cell therapy at Murdoch Veterinary Hospital to a strained suspensory ligament in his off-foreleg.

Vets found Smoko had strained the ligament when he pulled up sore following his shock sixth as a $2 favourite to Shining Knight in last Tuesday's Colonel Reeves Stakes (1100m) at Ascot.

Co-trainer Ross Price said Smoko would be sidelined for months.

"He will go to Murdoch where they will look at him and see about stem cell therapy," he said.

"In about 10 days we will take him up there and see what they can do. It is then going to be five months off and hoping."

Smoko was a $6.50 chance in Saturday week's Winterbottom Stakes (1200m) before he was scratched. WA's hopes of winning back the Group 1 weight-for-age hinge on Magnifisio, Shining Knight and Testamezzo, with Barakey in doubt after struggling to recover from a virus.

"He is still feeling flat and I will have to wait and see if he improves over the next few days," trainer Jim Taylor said.

Magnifisio firmed from $12 into $8 on the TAB yesterday following her strong win at her debut over 1400m in Saturday's Group 2 Lee-Steere Stakes at Ascot.

Melbourne sprinters Angelic Light, Moment Of Change and reigning champion Buffering dominate betting at $4.30, $6.50 and $7.50.

Continue reading here:
Stem cell therapy for sidelined star Smoko

Dopamine-making neurons derived from human embryonic stem cells.

See correction at end of article.

A rat model of Parkinson's disease has been successfully treated with neurons derived from human embryonic stem cells, according to a study led by Swedish scientists. Its a promising sign for scientists at The Scripps Research Institute and Scripps Health who hope to perform similar therapy on Parkinsons patients, using artificial embryonic stem cells.

In rats and people, neurons that make the neurotransmitter dopamine are essential for normal movement. The cells are destroyed in Parkinson's, leading to the difficulty in movement that characterizes the disease.

Researchers transplanted dopamine-producing cells grown from human embryonic stem cells into the brains of rats whose own dopamine-making neurons had been destroyed. The rats were immune-suppressed so they would not reject the cells. Within five months, the transplanted cells boosted dopamine production to normal levels, restoring normal movement in the rats.

The study was published Thursday in the journal Cell Stem Cell. The senior author was Malin Parmar of Lund University in Lund, Sweden.

The results support the Scripps approach of using the artificial embryonic stem cells, called induced pluripotent stem cells, said Jeanne Loring, who heads the Center for Regenerative Medicine at The Scripps Research Institute in La Jolla. Loring is part of a group called Summit 4 Stem Cell that's raising funds to treat eight Parkinson's patients with their own IPS cells.

Particularly significant is the study's comparison of the effects of dopamine-making neurons derived from fetal cells to that of embryonic stem cells, Loring said by email.

"In the 1980s and 1990s, there were several clinical trials that showed that grafts of fetal brain containing the precursors of dopamine neurons could reverse the effects of Parkinson's disease in some patients," Loring said. "We, and the others developing stem cell therapies, based our plans on the results of those studies, but no one had ever directly compared fetal tissue and human pluripotent stem cell-derived dopamine neurons in an animal model of PD."

Induced pluripotent stem cells appear to have much the same capacity as human embryonic stem cells to generate different tissues and organs.

Read the original:
Parkinson's stem cell therapy works in rats

The day Olivia Cox was diagnosed with Type 1 diabetes at age 16, her mother vowed to find a cure.

"I said to her, "there's someone walking this Earth who has been cured of diabetes, and I'm going to find him," Ruth Cox said.

Cox's search started with a call to Harvard University and ended with a family trip to Lima, Peru. It was at a clinic there that now 18-year-old Olivia and her father, Jeff, 54, who also has diabetes, received an infusion of stem cells designed to wipe out diabetes in their bodies or, at the very least, lessen its impact. The treatment illegal in the United States cost $70,000 for both father and daughter. Two months later, the Niskayuna family is waiting for a transformation and wondering if, in their desperation for a cure, they were snookered by false promises.

Because stem cells can be programmed to become anything from heart muscle to toenails, stem cell therapy can hypothetically be used to treat anything, from baldness to Lou Gehrig's Disease. But the study of regenerative medicine is still nascent in the United States, where it is restricted to procedures that use the patient's own cells, and it has been primarily used in treating cancer a procedure that saved Ruth Cox 13 years ago, when she had breast cancer.

Stem cell treatment using donor cells is more common elsewhere in the world, but with varying results and none that could be described as a cure. An executive order from President Barack Obama opened up funding for stem cell research and there are now more than 4,000 clinical trials under way, some on animals and some recruiting people with various ailments.

The American Diabetes Association strongly supports stem cell research, according to a statement posted on its website, which reads in part:

"Scientists from across the United States and throughout the world, including those involved with the American Diabetes Association believe that stem cell research, especially embryonic stem cell research, holds great promise in the search for a cure and better treatments for diabetes."

Jeff Cox, diagnosed with Type 1 diabetes when he was 11, has suffered none of the complications that often come with the disease neuropathy, loss of vision and heart disease. But Cox said living with diabetes is hell. He pricks his finger at least a dozen times a day to check his blood sugar level, because it is a more precise reading than the glucose monitor he wears. He also wears a pump that he programs to inject him with insulin automatically based on his diet and exercise each day. All the therapies used to treat diabetes are designed to intervene where the pancreas has gone awry.

In Type 1 diabetes, the pancreas doesn't produce insulin due to an autoimmune attack against the beta cell that produces insulin the hormone that converts glucose into energy our bodies need to survive. The Coxes didn't want their daughter to face a lifetime of managing her diabetes. They wanted a cure, and they were willing to take a risk to find it.

In order to treat diabetes with stem cell therapy, pancreatic stem cells isolated from umbilical cord blood that are programmed to produce insulin, plus autologous mesenchymal stem cells from the patient's bone marrow, are injected. Once in the pancreas, the cells are supposed to replicate themselves, gradually replacing the non-insulin producing cells in the host's pancreas. The treatment is conducted in Peru, China, Russia and India and elsewhere, but Zubin Master, a bioethicist at Albany Medical College, said the risks of traveling abroad for stem cell therapy range from paying for an expensive treatment that doesn't work, to cancer and death.

See original here:
Family's desperate bet on a diabetes cure

Stem Cell Therapy for Multiple Sclerosis: Ron McGill
Ron McGill suffers from relapsing-remitting multiple sclerosis. He was started experiencing symptoms in 2009 but was not diagnosed with MS until January of 2013. He received several infusion...

By: http://www.cellmedicine.com

See the original post:
Stem Cell Therapy for Multiple Sclerosis: Ron McGill - Video

Stem Cell Therapy for Pets in Central Florida
http://www.NewmanVets.com Call your local Newman Veterinary Center for more information about stem cell therapy for pets. https://www.youtube.com/watch?v=7X23bmsy0Q8 feature=youtu.be.

By: Newman Veterinary Centers

View original post here:
Stem Cell Therapy for Pets in Central Florida - Video

David C P. Chen, MD., MHP - Stem Cell Therapy Q A1
David C P. Chen, MD., MHP - Stem Cell Therapy Q A1.

By: advanced anti aging center

See the article here:
David C P. Chen, MD., MHP - Stem Cell Therapy Q&A1 - Video

David C P. Chen, MD., MHP - Stem Cell Therapy Q A2

By: advanced anti aging center

Read more here:
David C P. Chen, MD., MHP - Stem Cell Therapy Q&A2 - Video

New research from McLean Hospital and the Harvard Stem Cell Institute has shown that stem cell therapy reduces seizures in mice.

Researchers used an animal model to transplant seizure-inhibiting, human embryonic stem cell-derived neurons into the brains of mice that had a common form of epilepsy. Half of the mice that received the transplanted neurons no longer had seizures, while the other half experienced a significant drop in seizure frequency.

The transplanted neurons integrated into the mouse brains and began to receive neuronal activity. The neurons then released GABA, an inhibitory response that reversed the electrical hyperactivity that causes seizure.

Previous studies showed increasing inhibition in the epileptic brain can help control the seizure and also a lot of anti-epilepsy drugs are mimicking this GABA, so many of them worked by binding to the GABA receptors, researcher Sangmi Chung, assistant professor of psychiatry at Harvard, told FoxNews.com.

Researchers initially set out to test the functionality of human neurons, but later decided to test their effect on epilepsy because it is such a devastating disease. About 30 percent of people do not respond to seizure drugs and one out of 26 people will be affected by seizures in their lifetime, Chung said.

Over 65 million people worldwide are affected by epileptic seizures, which can cause convulsions, loss of consciousness and other neurological symptoms. Patients are treated with anti-seizure drugs, and may choose to have a portion of their brain removed.

Because mouse cells mature more quickly than human cells within weeks instead of years it was unclear how long a stem cell transplant in a human would take before becoming effective, Chung noted.

If we compare it with the mouse [model], we believe it will be years, not weeks, she said.

However, the study found that, even without full maturation, the cells integrated into the epileptic mouse brains, receive signals and release GABA, therefore preventing seizures.

I think its really good news in terms of transplantation even maturing, not fully mature [cells] still work, Chung said.

Go here to read the rest:
Stem cell transplants may help reduce seizures, study says

Freeport, Grand Bahama (PRWEB) November 05, 2014

Okyanos is the first to receive regulatory approval from the National Stem Cell Ethics Committee (NSEC) to provide adult stem cell therapy in its new state-of-the-art facility and has now begun treating patients. The licensing includes approval for cardiac cell therapy, as well as cell therapy for tissue ischemia, autoimmune diseases, and other chronic neurological and orthopedic conditions. The licensing criteria requires that approved protocols be supported by peer-reviewed papers showing substantial evidence of safety and efficacy.

"As the leader in cell therapy, Okyanos is very proud to bring a new standard of care and a better quality of life to patients who are looking for new options for unmet healthcare needs. said Matt Feshbach, CEO and co-founder of Okyanos. Adipose (fat)- derived stem and regenerative cells (ADRCs) are known to restore blood flow, modulate the immune system, reduce inflammation and prevent further cell death after a wound, helping the body begin the process of healing itself.

Adult stem cell therapy has emerged as a new treatment alternative for those who want to live a more normal life but are restricted in these activities due to their medical conditions. Just 50 miles from the US shore, Okyanos cell therapy is available to patients with severe heart disease including coronary artery disease (CAD) and congestive heart failure (CHF) as well as patients with auto-immune diseases, orthopedic, neurological and urological conditions. Okyanos cell therapy is performed in their new state-of-the-art facility built to exceed U.S. surgical center standards.

With the regulatory and licensing approvals for adult stem cell therapy, Okyanos is the first to treat patients with cell therapy for severe heart disease and other unmet medical conditions based on a combination of internationally approved cell processing technology, technical papers, clinical trials and in-clinic use which provide the basis for a new standard of care.

Patients can contact Okyanos at http://www.okyanos.com or by calling toll free at 1-855-659-2667.

About Okyanos: (Oh key AH nos) Based in Freeport, Grand Bahama, Okyanos brings a new standard of care and a better quality of life to patients with coronary artery disease, tissue ischemia, autoimmune diseases, and other chronic neurological and orthopedic conditions. Okyanos Cell Therapy utilizes a unique blend of stem and regenerative cells derived from patients own adipose (fat) tissue which helps improve blood flow, moderate destructive immune response and prevent further cell death. Okyanos is fully licensed under the Bahamas Stem Cell Therapy and Research Act and adheres to U.S. surgical center standards. The literary name Okyanos, the Greek god of the river Okyanos, symbolizes restoration of blood flow.

Read the rest here:
Okyanos Treats First Patients with Cell Therapy

PURTIER LIVE STEM CELL THERAPY
PURTIER INTRODUCTION IN CHINESE Please contact Pearly @ +65 9338 9541 / +65 9189 7351 for more details.

By: Purtier30

View post:
PURTIER LIVE STEM CELL THERAPY - Video

JANUARY 2014 State of the Industry Briefing at EBD's Biotech Showcase Jan 13. San Francisco, CA EBD's Biotech Showcase: Regenerative Medicine Industry Track Jan 13-15. San Francisco, CA ECI's Conference on Scale-Up and Manufacturing of Cell-Based Therapies Jan 6-9. San Diego, CA International Conference on Cell Therapy for Cardiovascular Disease Jan 22-24. New York, NY Phacilitate's Cell and Gene Therapy Forum Jan 27-29. Washington, DC FEBRUARY 2014 RRY's New York Stem Cell Summit Feb 18. New York, NY STEMSO's International Stem Cell Society Conference Feb 19-22. Freeport, Grand Bahama BMT Tandem Meetings Feb 26-Mar.Grapevine (Dallas), TX MARCH 2014 Danish Stem Cell Symposium Mar 7-8. Hillerd, Denmark ISBioTech Spring Mtg - Cellular Therapies Track Mar 10-12. Washington, DC AAT's Advanced Therapies Summit Mar 12-13. Turin, Italy ISSCR/SBE International Conference on Stem Cell Engineering Mar 16-19. Coronado, CA Congress on Stem Cell and Cell Therapies Mar 2023. Koceli, Turkey FDA and the Changing Paradigm for HCT/P Regulation Mar 24-26. Bethesda, MD BIRAXs' UK-Israel Regenerative Medicine Conference Mar 25-26. Haifa, Israel ARM's RegenMed Investor Day Mar 26. New York, NY. Regenerative Medicine Workshop at Hilton Head Mar 26-29 . Hilton Head, SC Cancer Immunotherapy: A Long-Awaited Reality Mar 27. NYC, NY. FDA Workshop: Synergizing Efforts in Standards Development for Cellular Therapies and Regenerative Medicine Public Mar 31. Silver Spring, MD.

APRIL 2014 Select Biosciences' Clinical Translation of Stem Cells Apr 21-22. Palm Springs, AZ ISCT Annual Meeting Apr 23-26. Paris, France GTCBio's Stem Cell Summit Apr 23-25. Boston, MA ARMs Annual Dinner & Legislative Fly-In Apr 28-9. Washington, DC.

MAY 2014 GeneExpression Systems' Stem Cells and Cell Signaling Mtg on Assays to Regenerative Medicine, Tissue Engineering and Therapeutics May 5-6. Waltham-Boston, MA Regenerative Medicine Foundation Symposium May 5-7. San Francisco, CA CHIsAdoptive T Cell Therapy:New Targets and Strategies for Immune Driven Diseases (part of the Tenth Annual PEGS: the essential protein engineering summit) May 7-8. Boston, MA ASGCT - American Society of Gene and Cell Therapy Mtg May 21-24. Washington, DC Terrapinn's World Stem Cells and Regenerative Medicine Congress May 20-22. London, UK JUNE 2014 PDA Europe: Advanced Therapy Medicinal Products Jun 3-4. Madrid, Spain The Orthobiologic Institute's PRP and Regenerative Medicine Symposium Jun 6-7. Los Angeles, CA Israstem Jun 10-11. Ramat, Gan. Israel TERMIS EU Mtg Jun 10-14. Genova, Italy ISSCR - International Society for Stem Cell Research Mtg Jun 18-21. Vancouver, BC, Canada Cell Tracking Symposium June 20. London, ON

BIO International Convention(with BPI BioProcess Theater) Jun 23-26. San Diego, CA ARM Networking Reception @BIO June 24. San Diego, CA OMIC'sCell Science and Stem Cell Research Jun 24-26. Valencia, Spain JULY 2014 The Business of Regenerative Medicine: New Therapies, New Models July 14-16. Toronto, ON Regenerative Medicine Essentials: The Fundamentals to the Future. July 21-25.Winston-Salem, NC

AUGUST 2014 CHI'sCell Therapy Bioproduction (part of the Bioprocessing Summit) Aug 18-22. Boston, MA Rejuvenation Biotechnology: Emerging Regenerative Medicine Solutions for the Diseases of Aging conference Aug 21-23. Santa Clara, CA.

SEPTEMBER 2014 Terrapinn's Stem Cells USA and Regenerative Medicine Congress Sep 15-16. Boston, MA IBC's Cell Therapy Bioprocessing Sep 15-16. Arlington, VA TERMIS Asia Pacific Mtg Sep 24-17. Daegu, S. Korea

OCTOBER 2014 Cancer Immunotherapy 2014 Oct. 6. New York City, NY ARM's Stem Cell Meeting on the Mesa Oct 7-9. La Jolla, CA Fraunhofer Life Science Symposium"Medicinal Stem Cell Products Oct 9-10. Leipzig, Germany Translational Regenerative Medicine Congress Oct 21-22. Leipzig, Germany CCRM-SCN Till and McCulloch Meetings Oct 27-29. Ottawa, ON, Canada OMICS' International Conference and Exhibition on Cell and Gene Therapy Oct 27-29. Las Vegas, NV

NOVEMBER 2014 ISSCR/SSCS Global Controls in Stem Cells Nov 5-7, 2014. Singapore Society for Immunotherapy of Cancer Annual Meeting Nov 6-9. National Harbor, MD International Conference on Stem Cells and Cancer (ICSCC-2014): Proliferation, Differentiation and Apoptosis Nov 8-10. New Delhi, India IFATS Annual Mtg Nov 13-16. Amsterdam, NL BIT's World Congress of Regenerative Medicine & Stem Cells (RMSC2014) Nov 13-16.Haikou, China Commercial Translation of Regenerative Medicine Nov/Dec ??. London, UK DECEMBER 2014 Cell Therapy Manufacturing Dec 3-4. Brussels, Belgium World Stem Cell Summit Dec 3-5. San Antonio, TX TERMIS Americas Mtg Dec 13-16. Washington, DC If I've missed an event you'd like to see added, please email me at lbuckler [at] celltherapygroup [dot] com.

Read more here:
Cell Therapy Blog: Cell Therapy Conferences 2014